Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2011, Article ID 127587, 15 pages
http://dx.doi.org/10.1155/2011/127587
Research Article

Dual Specificity Phosphatase 1 Regulates Human Inducible Nitric Oxide Synthase Expression by p38 MAP Kinase

1The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Medisiinarinkatu 3, 33014 Tampere, Finland
2The Kennedy Institute of Rheumatology, Imperial College London, London W6 8LH, UK

Received 17 December 2010; Accepted 15 February 2011

Academic Editor: Fulvio D'Acquisto

Copyright © 2011 Tuija Turpeinen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Bogdan, “Nitric oxide and the immune response,” Nature Immunology, vol. 2, no. 10, pp. 907–916, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Korhonen, A. Lahti, H. Kankaanranta, and E. Moilanen, “Nitric oxide production and signaling in inflammation,” Current Drug Targets, vol. 4, no. 4, pp. 471–479, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Vuolteenaho, T. Moilanen, R. G. Knowles, and E. Moilanen, “The role of nitric oxide in osteoarthritis,” Scandinavian Journal of Rheumatology, vol. 36, no. 4, pp. 247–258, 2007. View at Google Scholar · View at Scopus
  4. J. R. Kanwar, R. K. Kanwar, H. Burrow, and S. Baratchi, “Recent advances on the roles of NO in cancer and chronic inflammatory disorders,” Current Medicinal Chemistry, vol. 16, no. 19, pp. 2373–2394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. J. Lowenstein, E. W. Alley, P. Raval et al., “Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 20, pp. 9730–9734, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Farlik, B. Reutterer, C. Schindler et al., “Nonconventional initiation complex assembly by STAT and NF-κB transcription factors regulates nitric oxide synthase expression,” Immunity, vol. 33, no. 1, pp. 25–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Pautz, J. Art, S. Hahn, S. Nowag, C. Voss, and H. Kleinert, “Regulation of the expression of inducible nitric oxide synthase,” Nitric Oxide, vol. 23, no. 2, pp. 75–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. E. De Vera, R. A. Shapiro, A. K. Nussler et al., “Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 3, pp. 1054–1059, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. B. S. Taylor, M. E. de Vera, R. W. Ganster et al., “Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene,” The Journal of Biological Chemistry, vol. 273, no. 24, pp. 15148–15156, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. R. W. Ganster, B. S. Taylor, L. Shao, and D. A. Geller, “Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8638–8643, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Kristof, J. Marks-Konczalik, and J. Moss, “Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation,” The Journal of Biological Chemistry, vol. 276, no. 11, pp. 8445–8452, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kleinert, T. Wallerath, G. Fritz et al., “Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-κB-signaling pathways,” British Journal of Pharmacology, vol. 125, no. 1, pp. 193–201, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Fechir, K. Linker, A. Pautz et al., “Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene,” Molecular Pharmacology, vol. 67, no. 6, pp. 2148–2161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Korhonen, K. Linker, A. Pautz, U. Förstermann, E. Moilanen, and H. Kleinert, “Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase,” Molecular Pharmacology, vol. 71, no. 5, pp. 1427–1434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Lahti, U. Jalonen, H. Kankaanranta, and E. Moilanen, “c-Jun NH-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages,” Molecular Pharmacology, vol. 64, no. 2, pp. 308–315, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Vodovotz, C. Bogdan, J. Paik, Q. W. Xie, and C. Nathan, “Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β,” Journal of Experimental Medicine, vol. 178, no. 2, pp. 605–613, 1993. View at Google Scholar · View at Scopus
  17. R. Korhonen, A. Lahti, M. Hämäläinen, H. Kankaanranta, and E. Moilanen, “Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages,” Molecular Pharmacology, vol. 62, no. 3, pp. 698–704, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hämäläinen, R. Korhonen, and E. Moilanen, “Calcineurin inhibitors down-regulate iNOS expression by destabilising mRNA,” International Immunopharmacology, vol. 9, no. 2, pp. 159–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Rodriguez-Pascual, M. Hausding, I. Ihrig-Biedert et al., “Complex contribution of the 3'-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene: involvement of the RNA-binding protein HuR,” The Journal of Biological Chemistry, vol. 275, no. 34, pp. 26040–26049, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Linker, A. Pautz, M. Fechir, T. Hubrich, J. Greeve, and H. Kleinert, “Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR,” Nucleic Acids Research, vol. 33, no. 15, pp. 4813–4827, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Pautz, K. Linker, T. Hubrich, R. Korhonen, S. Altenhöfer, and H. Kleinert, “The polypyrimidine tract-binding protein (PTB) is involved in the post-transcriptional regulation of human inducible nitric oxide synthase expression,” The Journal of Biological Chemistry, vol. 281, no. 43, pp. 32294–32302, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Pautz, K. Linker, S. Altenhöfer et al., “Similar regulation of human inducible nitric-oxide synthase expression by different isoforms of the RNA-binding protein AUF1,” The Journal of Biological Chemistry, vol. 284, no. 5, pp. 2755–2766, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” Science, vol. 298, no. 5600, pp. 1911–1912, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Rincón and R. J. Davis, “Regulation of the immune response by stress-activated protein kinases,” Immunological Reviews, vol. 228, no. 1, pp. 212–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Cuenda and S. Rousseau, “p38 MAP-Kinases pathway regulation, function and role in human diseases,” Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1358–1375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. D. Ashwell, “The many paths to p38 mitogen-activated protein kinase activation in the immune system,” Nature Reviews Immunology, vol. 6, no. 7, pp. 532–540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Ono and J. Han, “The p38 signal transduction pathway Activation and function,” Cellular Signalling, vol. 12, no. 1, pp. 1–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Han, J. D. Lee, L. Bibbs, and R. J. Ulevitch, “A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells,” Science, vol. 265, no. 5173, pp. 808–811, 1994. View at Google Scholar · View at Scopus
  29. A. Pietersma, B. C. Tilly, M. Gaestel et al., “P38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level,” Biochemical and Biophysical Research Communications, vol. 230, no. 1, pp. 44–48, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. I. N. Foltz, J. C. Lee, P. R. Young, and J. W. Schrader, “Hemopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen-activated protein kinase pathway,” The Journal of Biological Chemistry, vol. 272, no. 6, pp. 3296–3301, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Wang, G. Zhou, M. C. T. Hu, Z. Yao, and T. H. Tan, “Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor β (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF β signal transduction,” The Journal of Biological Chemistry, vol. 272, no. 36, pp. 22771–22775, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Marie, S. Roman-Roman, and G. Rawadi, “Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins,” Infection and Immunity, vol. 67, no. 2, pp. 688–693, 1999. View at Google Scholar · View at Scopus
  33. J. L. E. Dean, M. Brook, A. R. Clark, and J. Saklatvala, “p38 Mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes,” The Journal of Biological Chemistry, vol. 274, no. 1, pp. 264–269, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. K. R. Mahtani, M. Brook, J. L. E. Dean, G. Sully, J. Saklatvala, and A. R. Clark, “Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability,” Molecular and Cellular Biology, vol. 21, no. 19, pp. 6461–6469, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Lahti, H. Kankaanranta, and E. Moilanen, “P38 mitogen-activated protein kinase inhibitor SB203580 has a bi-directional effect on iNOS expression and NO production,” European Journal of Pharmacology, vol. 454, no. 2-3, pp. 115–123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. D. C. Underwood, R. R. Osborn, S. Bochnowicz et al., “SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung,” American Journal of Physiology, vol. 279, no. 5, pp. L895–L902, 2000. View at Google Scholar · View at Scopus
  37. A. M. Badger, D. E. Griswold, R. Kapadia et al., “Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis,” Arthritis and Rheumatism, vol. 43, no. 1, pp. 175–183, 2000. View at Google Scholar · View at Scopus
  38. B. L. Burnette, S. Selness, R. Devraj et al., “SD0006: a potent, selective and orally available inhibitor of p38 kinase,” Pharmacology, vol. 84, no. 1, pp. 42–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Lang, M. Hammer, and J. Mages, “DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response,” Journal of Immunology, vol. 177, no. 11, pp. 7497–7504, 2006. View at Google Scholar · View at Scopus
  40. T. Boutros, E. Chevet, and P. Metrakos, “Mitogen-Activated Protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer,” Pharmacological Reviews, vol. 60, no. 3, pp. 261–310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Hammer, J. Mages, H. Dietrich et al., “Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock,” Journal of Experimental Medicine, vol. 203, no. 1, pp. 15–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. K. V. Salojin, I. B. Owusu, K. A. Millerchip, M. Potter, K. A. Platt, and T. Oravecz, “Essential role of MAPK phosphatase-1 in the negative control of innate immune responses,” Journal of Immunology, vol. 176, no. 3, pp. 1899–1907, 2006. View at Google Scholar · View at Scopus
  43. H. Chi, S. P. Barry, R. J. Roth et al., “Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2274–2279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. R. Clark, J. R. S. Martins, and C. R. Tchen, “Role of dual specificity phosphatases in biological responses to glucocorticoids,” The Journal of Biological Chemistry, vol. 283, no. 38, pp. 25765–25769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. T. J. Calvert, L. G. Chicoine, Y. Liu, and L. D. Nelin, “Deficiency of mitogen-activated protein kinase phosphatase-1 results in iNOS-mediated hypotension in response to low-dose endotoxin,” American Journal of Physiology, vol. 294, no. 4, pp. H1621–H1629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Wang, X. Meng, J. R. Kuhlman et al., “Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria,” Journal of Immunology, vol. 178, no. 8, pp. 5312–5320, 2007. View at Google Scholar · View at Scopus
  47. T. Turpeinen, R. Nieminen, E. Moilanen, and R. Korhonen, “Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 1, pp. 310–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Nieminen, R. Korhonen, T. Moilanen, A. R. Clark, and E. Moilanen, “Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1650–1659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Dorfman, D. Carrasco, M. Gruda, C. Ryan, S. A. Lira, and R. Bravo, “Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts,” Oncogene, vol. 13, no. 5, pp. 925–931, 1996. View at Google Scholar · View at Scopus
  50. J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein kinase inhibitors: a further update,” Biochemical Journal, vol. 408, no. 3, pp. 297–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. Q. Zhao, X. Wang, L. D. Nelin et al., “MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock,” Journal of Experimental Medicine, vol. 203, no. 1, pp. 131–140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Zakkar, H. Chaudhury, G. Sandvik et al., “Increased endothelial mitogen-activated protein kinase phosphatase-1 expression suppresses proinflammatory activation at sites that are resistant to atherosclerosis,” Circulation Research, vol. 103, no. 7, pp. 726–732, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. W. J. Frazier, X. Wang, L. M. Wancket et al., “Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice,” Journal of Immunology, vol. 183, no. 11, pp. 7411–7419, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. S. C. Linn, P. J. Morelli, I. Edry, S. E. Cottongim, C. Szabó, and A. L. Salzman, “Transcriptional regulation of human inducible nitric oxide synthase gene in an intestinal epithelial cell line,” American Journal of Physiology, vol. 272, no. 6, pp. G1499–G1508, 1997. View at Google Scholar · View at Scopus
  55. T. Nakamura, H. Suzuki, Y. Wada, T. Kodama, and T. Doi, “Fucoidan induces nitric oxide production via p38 mitogen-activated protein kinase and NF-κB-dependent signaling pathways through macrophage scavenger receptors,” Biochemical and Biophysical Research Communications, vol. 343, no. 1, pp. 286–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Bellmann, V. Burkart, J. Bruckhoff, H. Kolb, and J. Landry, “p38-Dependent enhancement of cytokine-induced nitric-oxide synthase gene expression by heat shock protein 70,” The Journal of Biological Chemistry, vol. 275, no. 24, pp. 18172–18179, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. S. M. Abraham, T. Lawrence, A. Kleiman et al., “Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1,” Journal of Experimental Medicine, vol. 203, no. 8, pp. 1883–1889, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Issa, S. Xie, N. Khorasani et al., “Corticosteroid inhibition of growth-related oncogene protein-α via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells,” Journal of Immunology, vol. 178, no. 11, pp. 7366–7375, 2007. View at Google Scholar · View at Scopus
  59. P. Bhavsar, M. Hew, N. Khorasani et al., “Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma,” Thorax, vol. 63, no. 9, pp. 784–790, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. T. T. Cornell, P. Rodenhouse, Q. Cai, L. Sun, and T. P. Shanley, “Mitogen-activated protein kinase phosphatase 2 regulates the inflammatory response in sepsis,” Infection and Immunity, vol. 78, no. 6, pp. 2868–2876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. M. G. Lechner, D. J. Liebertz, and A. L. Epstein, “Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells,” Journal of Immunology, vol. 185, no. 4, pp. 2273–2284, 2010. View at Publisher · View at Google Scholar
  63. R. Newton, E. M. King, W. Gong et al., “Glucocorticoids inhibit IL-1beta-induced GM-CSF expression at multiple levels: roles for the ERK pathway and repression by MKP-1,” The Biochemical Journal, vol. 427, no. 1, pp. 113–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Loda, P. Capodieci, R. Mishra et al., “Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis,” American Journal of Pathology, vol. 149, no. 5, pp. 1553–1564, 1996. View at Google Scholar · View at Scopus
  65. S. Vicent, M. Garayoa, J. M. López-Picazo et al., “Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients,” Clinical Cancer Research, vol. 10, no. 11, pp. 3639–3649, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. X. Liu, J. Wang, J. Guo, J. Wu, H. B. Lieberman, and Y. Yin, “DUSP1 is controlled by p53 during the cellular response to oxidative stress,” Molecular Cancer Research, vol. 6, no. 4, pp. 624–633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. V. Duric, M. Banasr, P. Licznerski et al., “A negative regulator of MAP kinase causes depressive behavior,” Nature Medicine, vol. 16, no. 11, pp. 1328–1332, 2010. View at Publisher · View at Google Scholar